Resources
7 Results (showing 1 - 7)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Supreme Court Room on Wednesday, March 5, 2020, at 2:30 PM
Posted 3/25/2021 (updated 4/5/2024)
Effective Leadership for Community Consortiums
Presenters will discuss why leadership is so important during these critical times, the intersections and choices facing leaders, responsive approaches, and engagement strategies for leaders. They will also provide strategies for consortium engagement based on the work of a Colorado Rural Communities Opioid Response Program (RCORP) grantee.
Posted 5/26/2021 (updated 4/10/2024)
What is the importance of responsive leadership? The complex choices facing leaders at every level of an organization require inclusive assessments and innovative solutions. Leaders face questions about who should be sitting around the table and which two or three responses might work to address a community consortium challenge. The presenter will review interventions for engaging in complex situations and a new normal.
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 7/26/2023 (updated 3/28/2024)
This session covered how primary prevention efforts fit within each of the various stages of the Continuum of Care Model. Attendees learned how to (1) engage community stakeholders from each of the 12 sectors and (2) evidence-based practices to not only inform, but to reduce stigma and to create open dialogue as it relates to SUD.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.